Cargando…
A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer
Head and neck squamous cell carcinomas (HNSCCs) are the sixth most common malignant neoplasm and more than 50% of patients succumb to this disease. HNSCCs are characterized by therapy resistance, which relies on the overexpression of anti-apoptotic proteins and on the aberrant regulation of the epid...
Autores principales: | Stauber, Roland H., Knauer, Shirley K., Habtemichael, Negusse, Bier, Carolin, Unruhe, Britta, Weisheit, Simona, Spange, Stephanie, Nonnenmacher, Frank, Fetz, Verena, Ginter, Torsten, Reichardt, Sigrid, Liebmann, Claus, Schneider, Günter, Krämer, Oliver H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292890/ https://www.ncbi.nlm.nih.gov/pubmed/22289787 |
Ejemplares similares
-
An otoprotective role for the apoptosis inhibitor protein survivin
por: Knauer, S K, et al.
Publicado: (2010) -
Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present
por: Huff, Sarah E., et al.
Publicado: (2022) -
The Efficacy of the Ribonucleotide Reductase Inhibitor Didox in Preclinical Models of AML
por: Cook, Guerry J., et al.
Publicado: (2014) -
Structure-guided design of anti-cancer ribonucleotide reductase inhibitors
por: Misko, Tessianna A., et al.
Publicado: (2019) -
Ribonucleotide Reductase Inhibitors: A New Look at an Old Target for Radiosensitization
por: Chapman, Tobias R., et al.
Publicado: (2012)